{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T03:20:56Z","timestamp":1774668056464,"version":"3.50.1"},"reference-count":27,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,9,1]]},"abstract":"<jats:p>Objective. To describe the extent of adherence to the recommended neonatal zidovudine (ZDV) regimen administered to infants who have been exposed to the human immunodeficiency virus (HIV) to prevent mother-to-child transmission of HIV and to determine which maternal factors are associated with compliance.<\/jats:p>\n               <jats:p>Methods. HIV-infected women (n = 87) who were participating in a larger study of perinatal transmission at 3 inner-city New York City hospitals were interviewed 2 to 6 weeks\u2019 postpartum to assess adherence to neonatal prophylaxis, social support, social network factors, and depression. In addition, plasma samples of 45 of their infants were assayed for ZDV levels.<\/jats:p>\n               <jats:p>Results. A majority of women (71%) administered all of the prescribed 4 daily doses in the previous week, as measured by interview; self-reported adherence was not associated with any maternal characteristics. In contrast, poor adherence, as measured by lower infant ZDV plasma levels, was associated with asymptomatic HIV illness in the mother and having 2 or more other children; good adherence, as indicated by higher ZDV levels, was associated with the presence of a maternal social support network, disclosure of HIV infection, and mothers\u2019 adherence to their own ZDV regimens during pregnancy. In multivariate regression analyses, maternal asymptomatic status (\u03b2 = \u22120.40) was associated with lower infant ZDV levels, and maternal adherence during pregnancy (\u03b2 = 0.37) was associated with higher levels.<\/jats:p>\n               <jats:p>Conclusions. Women who are HIV asymptomatic and lack a social support network are more likely not to comply with the recommended neonatal prophylactic regimen of antiretroviral therapy. Future studies should address the prenatal period and social network factors, such as disclosure of serostatus, and the custody of other children.<\/jats:p>","DOI":"10.1542\/peds.110.3.e35","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:17:55Z","timestamp":1092442675000},"page":"e35-e35","source":"Crossref","is-referenced-by-count":19,"title":["Maternal Adherence to the Zidovudine Regimen for HIV-Exposed Infants to Prevent HIV Infection: A Preliminary Study"],"prefix":"10.1542","volume":"110","author":[{"given":"Penelope A.","family":"Demas","sequence":"first","affiliation":[{"name":"AIDS Research Program, Department of Epidemiology and Social Medicine, Montefiore Medical Center, Bronx, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayris P.","family":"Webber","sequence":"additional","affiliation":[{"name":"AIDS Research Program, Department of Epidemiology and Social Medicine, Montefiore Medical Center, Bronx, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellie E.","family":"Schoenbaum","sequence":"additional","affiliation":[{"name":"AIDS Research Program, Department of Epidemiology and Social Medicine, Montefiore Medical Center, Bronx, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Weedon","sequence":"additional","affiliation":[{"name":"Medical and Health Research Association, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janis","family":"McWayne","sequence":"additional","affiliation":[{"name":"Medical and Health Research Association, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Enriquez","sequence":"additional","affiliation":[{"name":"AIDS Research Program, Department of Epidemiology and Social Medicine, Montefiore Medical Center, Bronx, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahrukh","family":"Bamji","sequence":"additional","affiliation":[{"name":"Metropolitan Medical Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevieve","family":"Lambert","sequence":"additional","affiliation":[{"name":"Bronx-Lebanon Medical Center, Bronx, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald M.","family":"Thea","sequence":"additional","affiliation":[{"name":"Medical and Health Research Association, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2002,9,1]]},"reference":[{"key":"2021121006250114600_R1","doi-asserted-by":"crossref","unstructured":"Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med.1994;331:1173\u20131180","DOI":"10.1056\/NEJM199411033311801"},{"key":"2021121006250114600_R2","unstructured":"Centers for Disease Control and Prevention. Recommendations of the US Public Health Service task force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Morb Mortal Wkly Rep.1994;43(RR-11):1\u201320"},{"key":"2021121006250114600_R3","doi-asserted-by":"crossref","unstructured":"Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med.1998;339:1409\u20131414","DOI":"10.1056\/NEJM199811123392001"},{"key":"2021121006250114600_R4","unstructured":"Centers for Disease Control and Prevention. U.S. Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. MMWR Morb Mortal Wkly Rep.1995;44(RR-7):1\u201315"},{"key":"2021121006250114600_R5","unstructured":"Centers for Disease Control and Prevention. Update: HIV counseling and testing using rapid tests\u2013United States, 1995. MMWR Morb Mortal Wkly Rep.1998;47:211\u2013215"},{"key":"2021121006250114600_R6","unstructured":"NY State Department of Health. Expedited HIV testing of women and newborns, L.D. No. HLT-51-98-00007-P. NY State Reg1999;May 19:8\u20139"},{"key":"2021121006250114600_R7","doi-asserted-by":"crossref","unstructured":"Watson DC, Farley JJ. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J.1999;18:682\u2013689","DOI":"10.1097\/00006454-199908000-00006"},{"key":"2021121006250114600_R8","doi-asserted-by":"crossref","unstructured":"Reddington C, Cohen J, Baldillo A, et al. Adherence to medication regimens among children with human immunodeficiency virus infection. Pediatr Infect Dis J.2000;19:1148\u20131153","DOI":"10.1097\/00006454-200012000-00005"},{"key":"2021121006250114600_R9","unstructured":"Ickovics JR, Thayaparan B, Ethier KA. Women and AIDS: a contextual analysis. In: Baum A, Revenson TA, Singer JE, eds. Handbook of Health Psychology. Mahwah, NJ: Lawrence Erlbaum; 2001:817\u2013839"},{"key":"2021121006250114600_R10","doi-asserted-by":"crossref","unstructured":"Thomas PA, Weedon J, Krasinkski K, et al. Maternal predictors of perinatal human immunodeficiency virus transmission. Pediatr Infect Dis J.1994;13:489\u2013495","DOI":"10.1097\/00006454-199406000-00005"},{"key":"2021121006250114600_R11","unstructured":"Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep.1992;41:1\u201319"},{"key":"2021121006250114600_R12","unstructured":"Hambleton J. Hematologic complications of HIV infection. In: Sande MA, Volberding PA, eds. The Medical Management of AIDS. Philadelphia, PA: WB Saunders; 1997:239\u2013246"},{"key":"2021121006250114600_R13","doi-asserted-by":"crossref","unstructured":"Richman DD, Fischl MA, Grieco MH. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-bind, placebo-controlled trial. N Engl J Med.1987;317:192\u2013197","DOI":"10.1056\/NEJM198707233170402"},{"key":"2021121006250114600_R14","doi-asserted-by":"crossref","unstructured":"Boucher FD, Modlin JF, Weller S, et al. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr.1993;122:137\u2013144","DOI":"10.1016\/S0022-3476(05)83507-3"},{"key":"2021121006250114600_R15","doi-asserted-by":"crossref","unstructured":"O\u2019Brien K, Wortman CB, Kessler RC, Joseph JG. Social relationships of men at risk for AIDS. Soc Sci Med.1998;36:1161\u20131167","DOI":"10.1016\/0277-9536(93)90236-W"},{"key":"2021121006250114600_R16","doi-asserted-by":"crossref","unstructured":"Lackner JB, Joseph JG, Ostrow DG, et al. A longitudinal study of psychological distress in a cohort of gay men: effects of social support and coping strategies. J Nerv Mental Dis.1998;181:4\u201312","DOI":"10.1097\/00005053-199301000-00002"},{"key":"2021121006250114600_R17","doi-asserted-by":"crossref","unstructured":"Ickovics JR, Ethier KA, Koenig LJ, Wilson TE, Walter EB, Ferrando S. Infant birth weight among women with or at high risk for HIV infection: the impact of clinical, behavioral, psychosocial, and demographic factors. Health Psychol.2000;19:515\u2013523","DOI":"10.1037\/0278-6133.19.6.515"},{"key":"2021121006250114600_R18","doi-asserted-by":"crossref","unstructured":"Radloff L. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas.1977;1:385\u2013401","DOI":"10.1177\/014662167700100306"},{"key":"2021121006250114600_R19","unstructured":"Tabachnick BG, Fidell LS. Using Multivariate Statistics. New York, NY: HarperCollins; 1996"},{"key":"2021121006250114600_R20","doi-asserted-by":"crossref","unstructured":"Moodley D, Pillay K, Naidoo K, et al. Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours. J Clin Pharmacol.2001;41:732\u201341","DOI":"10.1177\/00912700122010636"},{"key":"2021121006250114600_R21","doi-asserted-by":"crossref","unstructured":"Mirochnick M, Capparelli E, Connor J. Pharmacokinetics of zidovudine in infants: a population analysis across studies. Clin Pharmacol Ther.1999;66:16\u201324","DOI":"10.1016\/S0009-9236(99)70049-4"},{"key":"2021121006250114600_R22","doi-asserted-by":"crossref","unstructured":"Lingren ML, Byers RH, Thomas P, et al. Trends in perinatal transmission of HIV\/AIDS in the United States. JAMA.1999;282:531\u2013538","DOI":"10.1001\/jama.282.6.531"},{"key":"2021121006250114600_R23","doi-asserted-by":"crossref","unstructured":"Fowler MG, Simonds RJ, Roongpisuthipong A. Update on perinatal HIV transmission. Pediatr Clin North Am.2000;47:21\u201338","DOI":"10.1016\/S0031-3955(05)70193-0"},{"key":"2021121006250114600_R24","doi-asserted-by":"crossref","unstructured":"Cooper ER, Nugent R, Diaz C, et al. After AIDS Clinical Trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. J Infect Dis.1996;174:1207\u20131211","DOI":"10.1093\/infdis\/174.6.1207"},{"key":"2021121006250114600_R25","doi-asserted-by":"crossref","unstructured":"Fiscus SA, Adimora AA, Schoenbach VJ, et al. Trends in human immunodeficiency virus (HIV) counseling, testing, and antiretroviral treatment of HIV-infected women and perinatal transmission in North Carolina. J Infect Dis.1999;180:99\u2013105","DOI":"10.1086\/314840"},{"key":"2021121006250114600_R26","doi-asserted-by":"crossref","unstructured":"Bulterys M, Fowler MG. Prevention of HIV infection in children. Pediatr Clin North Am.2000;47:241\u2013260","DOI":"10.1016\/S0031-3955(05)70203-0"},{"key":"2021121006250114600_R27","doi-asserted-by":"crossref","unstructured":"Newschaffer CJ, Cockcroft J, Hauck WW, Fanning T, Turner BJ. Improved birth outcomes associated with enhanced Medicaid prenatal care in drug-using women infected with the human immunodeficiency virus. Obstet Gynecol.1998;91:885\u2013891","DOI":"10.1097\/00006250-199806000-00003"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/110\/3\/e35\/1115998\/pe0902000e35.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/110\/3\/e35\/1115998\/pe0902000e35.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T14:42:43Z","timestamp":1639147363000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/110\/3\/e35\/64187\/Maternal-Adherence-to-the-Zidovudine-Regimen-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,9,1]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2002,9,1]]},"published-print":{"date-parts":[[2002,9,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.110.3.e35","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,9,1]]}}}